Obermeyer Wood Investment Counsel Lllp Sells 8,554 Shares of Johnson & Johnson (NYSE:JNJ)

Obermeyer Wood Investment Counsel Lllp cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.7% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 173,178 shares of the company’s stock after selling 8,554 shares during the quarter. Johnson & Johnson comprises 1.9% of Obermeyer Wood Investment Counsel Lllp’s investment portfolio, making the stock its 21st biggest holding. Obermeyer Wood Investment Counsel Lllp’s holdings in Johnson & Johnson were worth $27,144,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Raymond James & Associates raised its stake in Johnson & Johnson by 0.4% during the fourth quarter. Raymond James & Associates now owns 6,061,707 shares of the company’s stock valued at $950,112,000 after buying an additional 26,982 shares during the last quarter. Ninety One UK Ltd raised its stake in Johnson & Johnson by 0.3% during the fourth quarter. Ninety One UK Ltd now owns 4,436,013 shares of the company’s stock valued at $695,301,000 after buying an additional 12,867 shares during the last quarter. DekaBank Deutsche Girozentrale raised its stake in Johnson & Johnson by 4.8% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 4,396,416 shares of the company’s stock valued at $688,198,000 after buying an additional 200,193 shares during the last quarter. Stifel Financial Corp raised its stake in Johnson & Johnson by 2.9% during the third quarter. Stifel Financial Corp now owns 4,306,268 shares of the company’s stock valued at $670,726,000 after buying an additional 120,891 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its stake in Johnson & Johnson by 22.2% during the third quarter. Envestnet Asset Management Inc. now owns 3,957,429 shares of the company’s stock valued at $616,370,000 after buying an additional 719,472 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on JNJ shares. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Bank of America decreased their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Morgan Stanley decreased their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, April 15th. Finally, Royal Bank of Canada decreased their price target on Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating for the company in a research note on Wednesday, April 17th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $175.86.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $148.53 on Thursday. The stock has a 50-day simple moving average of $155.69 and a two-hundred day simple moving average of $155.47. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16. The firm has a market capitalization of $357.92 billion, a PE ratio of 9.26, a P/E/G ratio of 2.46 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same quarter in the previous year, the company posted $2.68 earnings per share. Johnson & Johnson’s revenue for the quarter was up 2.3% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.34%. The ex-dividend date is Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is currently 29.68%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.